Answers are grounded in this paper and cite their sources.
TEX have a special advantage as potential cancer biomarkers. Their cargo emerges as a correlate of developing or progressing malignant disease; their phenotype mimics that of the tumor; and their functional reprogramming of immune cells provides a reading of the patients' immune status prior and post immunotherapy. Validation of TEX and T-cell-derived sEV as cancer biomarkers is an impending future task.
No takes yet. Share an insight, caveat, or question.
Czystowska et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: